Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

32 results about "Steatonecrosis" patented technology

Implants and methods for treating bone

An orthopedic implant comprising a deformable, expandable implant body configured for treating abnormalities in bones, such as compression fractures of vertebra, necrosis of femurs and the like. An exemplary implant body comprises a small cross-section threaded element that is introduced into a bone region and thereafter is expanded into a larger cross-section, monolithic assembly to provide a bone support. In one embodiment, the implant body is at least partly fabricated of a magnesium alloy that is biodegradable to allow for later tissue ingrowth.
Owner:DFINE INC

Regulation of transforming growth factor-beta (TGF-beta) gene expression in living cells via the application of specific and selective electric and electromagnetic fields

Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and / or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and / or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and / or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and / or β3 protein may be implicated.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Regulation of transforming growth factor-beta (TGF-beta) gene expression in living cells via the application of specific and selective electric and electromagnetic fields

Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and / or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and / or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and / or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and / or β3 protein may be implicated
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Steerable drill for minimally-invasive surgery

An embodiment in accordance with the present invention provides a continuum dexterous manipulator (CDM) with a specially designed flexible tool, to be used as a handheld or robotic steerable device for treatment of hard-tissue-related diseases. The CDM of the present invention works well in treatment of soft and sticky material (similar to a lesion) as well as milling the hard tissues (e.g. sclerotic liner of osteolytic lesions) and bone tumors. The present invention is also directed to flexible drilling tools as well as characterization and evaluation of integrating these tools with the CDM in curved-drilling of hard bone towards treatment of hard tissue related diseases (e.g. osteonecrosis or pelvic fracture). The present invention can also include use of various types of drill geometries, aspiration and irrigation, and endoscope view in curved-drilling and trajectory planning.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions

InactiveUS20080167513A1Heavy metal active ingredientsSkeletal disorderLegg-Calve-Perthes diseaseGlucocorticoid
A method for the treatment and / or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and / or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and / or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
Owner:OSTEOLOGIX AS

Medicine for treating osteoporosis and its preparing method and use

The patent application relates to a kind of osteoporosis treating medicine and its preparation process as well as its new use in treating fracture, osteoarthritis, osteonecrosis and climacteric syndrome. The medicine is prepared with epimedium, teasel root, red sage, anemarrhena rhizome, malaytea scurfpea fruit and rehmannia root. Clinical and animal experiment research shows that the medicine has higher curative effect and no side effect compared with other medicine for treating osteoporosis, and may be taken regularly.
Owner:GUOYAOJITUAN TONGJITANG (GUIZHOU) PHARMA CO LTD

Methods and Pharmaceutical Compositions for the Treatment of Bone Density Related Diseases

InactiveUS20130195863A1Decreased bone mineral densityIncreasing bone mineral densityOrganic active ingredientsPeptide/protein ingredientsGhosal hematodiaphyseal dysplasiaBone density
The invention relates to methods and pharmaceutical compositions for the treatment of bone density related diseases. More particularly, the present invention relates to a ROBO1 modulator for use in a method for the treatment of a bone mineral density related disease in a subject. In a particular embodiment the ROBO1 modulator is selected from the group consisting of small organic molecules, antibodies, aptamers or polypeptides. In another particular embodiment said bone mineral density related disease is selected from the group consisting of ghosal hematodiaphyseal dysplasia syndrome (GHDD), osteoporosis, osteoporosis associated to pseudoglioma, osteoporosis and oculocutaneous hypopigmentation syndrome, osteoporosis due to endocrinological dysfunction, osteogenesis imperfecta osteopenia, Paget's disease, osteomyelitis, hypercalcemia, osteonecrosis, hyperparathyroidism, lytic bone metastases, periodontitis, bone loss due to immobilization and osteoporosis associated with a disease selected from the group consisting of cachexia, anorexia, alopecia, rheumatoid arthritis, psoriatic arthritis, psoriasis, and inflammatory bowel disease.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM)

Regulation of fibroblastic growth factor-2 (FGF-2) gene expression in living cells with the application of specific and selective electric and electromagnetic fields

Methods and devices are described for the regulation of Fibroblastic Growth Factor-2 mRNA and / or FGF-2 protein in bone cells and other tissues via capacitive coupling or inductive coupling of specific and selective electric and / or electromagnetic fields to the bone cells or other tissues, where the specific and selective fields are generated by application of specific and selective signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective signals that generate electric and / or electromagnetic fields in the target tissue optimized for increase of FGF-2 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate FGF-2 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of osteoporosis, osteopenia, osteonecrosis, fresh bone fractures, fractures at risk, nonunion, bone defects, spine fusion, and / or other conditions in which FGF-2 protein has been implicated.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA

Medicine for preventing medicine-related osteonecrosis of jaw

PendingCN111467364AOrganic active ingredientsSkeletal disorderJaw OsteonecrosisOsteocyte
The invention discloses a medicine for preventing medicine-related osteonecrosis of the jaw. The medicine uses a DNA tetrahedron as an effective ingredient. Experiments show that the DNA tetrahedron can reverse the inhibitory effect of zoledronic acid, dexamethasone and other medicines on osteoclast, and can relatively well prevent medicine-related osteonecrosis of the jaw.
Owner:SICHUAN UNIV

Medicine for treating ischemic necrosis of head of femur and preparation method thereof

The composition of the Chinese medicine with the functions of effectively improving blood circulation of bone, raising volume of blood flow, reducing internal pressure of bone, inhibiting platelet aggregation, reducing osteonecrosis and promoting osteonecrosis regeneration for curing ischemic necrosis of femoral head is formed from 12 Chinese medicinal materials of notoginseng, ligusticum root, cordydalis tuber, Chinese angelica root, saussurea root, millettia root and stem and others.
Owner:郭永昌

Deferoxamine derivative compound with bone affinity, preparation method and application thereof

The invention develops a deferoxamine derivative with bone affinity, a preparation method and application thereof. More specifically, the invention provides a compound with a structure shown as formula (1) and its pharmaceutically acceptable salt, ester, amide, acyl halide, hydrate or solvate. The invention also provides a preparation method of the compound shown as formula (1) and application thereof in preparation of drugs for treatment of osteoporosis, osteonecrosis, delayed union or nonunion and bone defect. (formula I).
Owner:上海市伤骨科研究所

Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions

A method for the treatment and / or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and / or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia / osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and / or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
Owner:OSTEOLOGIX AS

Micropowder medicament for treating bone fractures and preparation method thereof

The invention relates to a micropowder medicament for treating bone fractures such as fracture, paralysis, osteonecrosis and bone fracture sequelae which are caused by trauma and the like and a preparation method thereof. The micropowder medicament comprises the following raw material medicaments: 4 to 7 parts of pyrite, 2 to 5 parts of herry rhodiola, 2 to 5 parts of frankincense, 2 to 5 parts of myrrh, 1 to 5 parts of safflower, 1 to 4 parts of garden balsam stem, 3 to 5 parts of prepared rhubarb, 2 to 5 parts of dioscorea nipponica, 3 to 6 parts of sea cucumber, 1 to 2 parts of gecko tail, 3 to 7 parts of pyrolusite and the like. The preparation method comprises the step of grinding the raw material medicaments into fine powder with the grain diameter of 300 to 1,000 meshes by a low-temperature freeze drying method, and preparing capsules for oral administration, or blending on site to form paste for external application; moreover, the medicament can be used for oral administration and external application simultaneously. The micropowder medicament has the excellent effect on closed fracture except for head injury, and particularly for traumatic patients who suffer from the bone fractures, both the trauma and the bone fractures can be treated. By the invention, more patients who suffer from the bone fractures and particularly serious patients do not suffer from amputation, do not need wheelchairs, and are recovered quickly, without sequela.
Owner:张智富 +1

Customized load-bearing and bioactive functionally-graded implant for treatment of osteonecrosis

ActiveUS20200315801A1Easy to integrateImpair invasionFemurCoatingsAnatomyBone ingrowth
An engineered medical device for treatment of osteonecrosis is provided where the size, porosity and ceramic content of the device can be personalized based on an individual patient's anatomical and physiological condition. The device distinguishes different segments mimicking anatomically-relevant cortical and cancellous segments, in which the cortical segments of the device can sustain mechanical loading, and the cancellous segment of the device can promote bone ingrowth, osteogenesis and angiogenesis.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Mesenchymal stromal cell bone graft material

The invention pertains to the use of mesenchymal stromal cells (MSC) in the treatment of bone disorders or injuries. The invention provides MSC and preparations of specifically pooled MSC for use in the manufacturing of bone graft material for implanting into or attaching to bones in order to enhance bone regeneration after surgery or injury, or to treat various bone disorders, such as osteonecrosis. The invention provides bone graft material, a method for its production, bone graft implants, and medical methods and uses of the inventive products.
Owner:JOHANN WOLFGANG GOETHE UNIV FRANKFURT AM MAIN

Traditional Chinese medicine for treating bone fracture and osteonecrosis and preparation method thereof

The invention particularly relates to a traditional Chinese medicine for treating bone fracture and osteonecrosis and a preparation method thereof. The traditional Chinese medicine for treating bone fracture and osteonecrosis is prepared from the following components in parts by mass: 2 to 4 parts of tree hair, 6 to 8 parts of dragon's blood, 8 to 10 parts of frankincense, 8 to 10 parts of myrrh, 5 to 7 parts of sambucus chinensis, 4 to 6 parts of semen momordicae, 30 to 40 parts of semen vaccariae, 2 to 4 parts of saffron crocus, 1 to 2 parts of fructus amomi rotundus, 2 to 4 parts of acanthopanax seeds, 7 to 10 parts of synthetic bone setting pills and 8 to 14 parts of radix notoginseng. The preparation method of the traditional Chinese medicine for treating bone fracture and osteonecrosis comprises the following steps: repeatedly calcining the synthesized bone setting pill, quenching with concentrated vinegar, breaking the wall into particles, sieving with a 240-mesh sieve, mixing with various medicines, sterilizing for 3-5 hours under an ultraviolet lamp, and filling into capsules or tabletting. The traditional Chinese medicine is short in bone fracture disease treatment time, good in effect and free of adverse reactions and side effects.
Owner:田力

Drug for treating femoral head necrosis and promoting bone regeneration

InactiveCN105582275ARestoration of sports weight bearing functionPromote regenerationDispersion deliverySkeletal disorderGlucocorticoidSide effect
The invention relates to a drug for disease treatment, in particular to a drug for treating femoral head necrosis and promoting bone regeneration. The drug is prepared through decoction of multiple traditional Chinese medicines including radix dipsaci asperoidis, fructus psoraleae, rhizoma drynariae, williams elder twig and rhizoma chuanxiong. The toxic and side effects are small. The drug is suitable for patients suffering from femoral head necrosis caused by long-term using of glucocorticoid, and patients suffering from femoral head avascular necrosis caused by long-term drinking or trauma, and can promote revascularization and repair of the necrosis part so as to treat femoral head necrosis and recover the moving and weight bearing functions of the femoral head to the maximum. The drug is mainly clinically applied to patients suffering from femoral head necrosis and osteonecrosis caused by glucocorticoid.
Owner:姜桂芹

Application of xylaria nigriper powder to preparation of medicines or healthcare food for preventing and treating osteoporosis and osteonecrosis

ActiveCN105998088ANormal microstructureNormal thicknessSkeletal disorderFood ingredient functionsBone densityRight femoral head
The invention discloses application of xylaria nigriper powder to preparation of medicines or healthcare food for preventing and treating osteoporosis and osteonecrosis. According to animal pharmacological experiments, the xylaria nigriper powder is capable of increasing bone mineral density and bone calcium and phosphorus content of osteoporosis model rats and increasing bone mass to make bone tissue microstructures tend to be normal; the xylaria nigriper powder is also capable of remarkably increasing femoral head capillary distribution of steroid-induced femoral head necrosis model rats and reducing fat deposition in femoral head bone tissues of the steroid-induced femoral head necrosis model rats; the xylaria nigriper powder is capable of remarkably increasing bone trabecula area fraction of alcoholic femoral head necrosis model rats and remarkably reducing empty lacuna count to realize normal morphology of bone cells in bone lacunae. According to clinical researches, the xylaria nigriper powder has a remarkable treatment effect on osteoporosis, steroid-induced femoral head necrosis and alcoholic femoral head necrosis. The xylaria nigriper powder is reliable in curative effect and high in safety and has a promising clinical application prospect.
Owner:雷允上药业集团有限公司

Bone recovering pill for treating bone necrosis

The invention belongs to the technical field of the traditional Chinese medicine, which in particular discloses a bone recovering pill for treating bone necrosis. The bone recovering pill is prepared from antler, radix clematidis, tortoise shell, twotooth achyranthes root, safflower, curculigo orchioides, prepared rehmannia root, radix notoginseng, angelica, radix morindae officinalis, astragalusroot, draconis sanguis, eucommia bark and rhizoma drynariae according to certain weight mixture ratio. The invention has the effects of induing menstruation to relieve menalgia, reinforcing the kidney to strengthen the bone, invigorating qi, tonifying the blood, promoting blood circulation and relieving the stasis of blood and has reasonable matching, coincidence of the medicine and the disease, positive curative effect and no side effect.
Owner:刘成玉

Medicinal composition for treating rheumatism and rheumatoid arthritis

The invention discloses a medicinal composition for treating rheumatism and rheumatoid arthritis. The medicinal composition consists of more than 20 medicaments, such as fortune's drynaria rhizome, processed nux vomica, scorpion, himalayan teasel root, frankincense, myrrh, diversifolious patrinia root and the like and has no side effect of chemical medicaments. The medicinal composition has the effects of drilling tendon, penetrating bone, activating tendons, expelling wind, relieving pain and eliminating stagnation and has the remarkable treatment effects of treating the rheumatism, the rheumatoid arthritis, scapulohumeral periarthritis, sciatica, gout, cervical spondylosis, herniated disk, hyperosteogeny, osteonecrosis and lupus erythematosus.
Owner:朱平东

Traditional Chinese medicine composition for treating rheumatism and bone disease and preparation method of composition

InactiveCN110314180AOvercome the disadvantage of recurrent painAntipyreticAnalgesicsCentipedeMyrrh
The invention discloses a traditional Chinese medicine composition for treating the rheumatism and bone disease. The traditional Chinese medicine composition is prepared from radix aconiti carmichaeli, frankincense, pseudo-ginseng, radix angelicae, radix aconiti, rhizoma drynariae, flos carthami, dried bodies of buthus martensii Karsch, rhizoma atractylodis, honey, radix puerariae, zaocys dhumnades, rhizoma sinomeni cauliset, centipedes, myrrh, cassia twigs, angelica sinensis, black kidney beans, cortex eucommiae, radix saposhnikoviae, radix astragali, radix paeoniae alba, radix liquiritiae, white mustard seeds and radix achyranthis bidentatae. The invention further provides a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition has the advantages that when the traditional Chinese medicine composition is applied to treatment of rheumatism pathogenic factors remaining in the body and various kinds of arthralgia of vein, jointsand muscles, the effective rate reaches 90% or above, and the cure rate is 96% or above; patients with the slight disease can be cured within 10-20 days; the patients with the severe diseases of the large and small swelled joints, upper and lower limb paralysis, osteonecrosis, rheumatoid arthritis, gout and rheumatic heart disease can be cured after taking the medicine for 3-4 treatment courses; but for complete cure of rheumatoid factors caused by long-term use of hormones, wrong treatment and delayed treatment, residues still exist in short time.
Owner:宿迁春铭健康管理咨询有限公司

Application of a traditional Chinese medicine composition in the preparation of medicines or health products for treating osteoporosis and osteonecrosis

The invention discloses an application of a traditional Chinese medicine composition in the preparation of medicines or health care products for treating osteoporosis and osteonecrosis. The traditional Chinese medicine composition of the present invention is made of Polygonum multiflorum, Polygonatum, Rehmannia glutinosa, Gorgon fruit, Ziheche, black sesame, Astragalus, Poria cocos, Chinese yam, American ginseng, Radix asparagus, Ophiopogon japonicus, pearl, amber, keel, arborvitae leaves, black soybean to make. Pharmacodynamic experiments show that the Chinese medicine composition of the present invention can increase the bone density of osteoporosis model rats and serum calcium and phosphorus levels; it can increase the distribution of capillaries in the femoral head of rats with steroid-induced necrosis of the femoral head, and reduce the distribution of steroid-induced necrosis of the femoral head model. Fat deposits in the femoral head bone tissue of rats, and clinical research results also show that the traditional Chinese medicine composition of the present invention has a good therapeutic effect on osteoporosis and femoral head necrosis. The traditional Chinese medicine composition provided by the invention has the advantages of good curative effect and small side effects in treating osteoporosis and osteonecrosis, and has good clinical application prospect.
Owner:雷允上药业集团有限公司

Compound for preventing osteonecrosis and/or promoting angiogenesis and pharmaceutical application thereof

The invention provides a compound for preventing osteonecrosis and / or promoting angiogenesis and pharmaceutical application thereof, and belongs to the field of biological medicine. The compound is prepared by taking DNA tetrahedral framework nucleic acid and KLT polypeptide as raw materials, and the molar ratio of the DNA tetrahedral framework nucleic acid to the KLT polypeptide is 1: (1-300). Experimental results show that the compound can effectively promote proliferation and migration of endothelial cells, promote vascularization and play a good role in preventing bisphosphonate-related jaw necrosis (BRONJ). It is worthy of noting that compared with DNA tetrahedral framework nucleic acid or KLT polypeptide, the compound has the advantages that the effects of promoting proliferation and migration of endothelial cells and promoting angiogenesis are remarkably improved, and the synergistic interaction effect is achieved. The compound provided by the invention can be used for preparing a medicine for promoting angiogenesis and a medicine for preventing osteonecrosis, and has a very good application prospect.
Owner:SICHUAN UNIV

Bone-invigorating pill

A traditional Chinese medicine prescription of the traditional Chinese medicine is ''bone hyperplasia'' and ''new traditional Chinese medicine'' (April of 1974) in the field of traditional Chinese medicines in China. The traditional Chinese medicine prescription comprises the following components: 45g of radix rehmanniae preparata, 30g of herba pyrolae, 30g of rhizoma drynariae, 30g of caulis spatholobi, 15g of cistanche, 15g of herba epimedii and beautiful galangal fruit as basic components, and astragalus membranaceus and apricot kernel added to form a ''bone-invigorating pill''. The bone-invigorating pill is prepared into a traditional water pill; and the bone-invigorating pill is prepared from nine traditional Chinese medicines: herba pyrolae, herba epimedii, rhizoma drynariae, caulis spatholobi, rhiizoma dioscoreae, astragalus membranaceus, apricot kernel, radix rehmanniae preparata and cistanche salsa according to the theory of kidneys governing bone of the traditional Chinese medicine. The old traditional Chinese medicine is similar to a modern medicine taking method, is convenient to carry and convenient and fast to take, can be taken through drinking and is reliable in curative effect, a patient with bone diseases gets rid of the pain of disability and inconvenience, osteonecrosis, cervical and lumber vertebra bulging, hyperplasia and various joints of the whole body are degeneratively changed (aged), osteoporosis in men and women and various bone diseases can be prevented and treated, and the patient walks fast as a young adult.
Owner:计怀安
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products